
Sign up to save your podcasts
Or


Maybe CAR T-cell therapy is the treatment of choice for your patient with triple-class refractory multiple myeloma? Join the discussion now!
Credit available for this activity expires: 3/23/2023
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/970643?src=mkm_podcast_addon_970643
By Medscape Podcasts4
77 ratings
Maybe CAR T-cell therapy is the treatment of choice for your patient with triple-class refractory multiple myeloma? Join the discussion now!
Credit available for this activity expires: 3/23/2023
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/970643?src=mkm_podcast_addon_970643

138 Listeners

322 Listeners

498 Listeners

102 Listeners

881 Listeners

13 Listeners

17 Listeners

288 Listeners

3,337 Listeners

1,154 Listeners

194 Listeners

88 Listeners

513 Listeners

367 Listeners

61 Listeners

26 Listeners

431 Listeners

370 Listeners